OncLive On Air

Mudit Chowdhary, MD, shares advice for family members living with patients with cancer, projects the long-term implications of the COVID-19 pandemic on clinical practice, provides insight on the effects of investigational treatments for patients with COVID-19, and details the protocols Rush University Medical Center has put into place to limit the spread of the virus.

In our exclusive interview, Dr. Karlan shares the rewarding moments and challenges she has encountered in the cancer space as a female oncologist, pivotal research she has been spearheaded that has lasting impacts on the field, and other developments in gynecologic cancers that are poised to change the landscape forever.

Howard A. "Skip" Burris, III, MD, FASCO, FACP, and Stephanie L. Graff, MD, discuss how the COVID-19 pandemic has affected cancer care, the collaborative efforts made between Sarah Cannon Research Institute and HCA to increase access to investigational COVID-19 treatments, and the steps ASCO has taken to ensure its members’ professional education and well-being during this time.

In our exclusive interview, Maria-Victoria Mateos, MD, PhD, discusses the FDA approval of the subcutaneous daratumumab formulation in multiple myeloma.

Bradley McGregor, MD, discusses the purpose of the guidelines, some of the main factors that influenced the recommendations in genitourinary cancers, and the impact of the pandemic on some of the most common treatment interventions such as immunotherapy, chemotherapy, and hormonal therapy, for patients with these malignancies.

In our exclusive interview, Thomas Herzog, MD, discusses the FDA approval of the combination of olaparib (Lynparza) and bevacizumab (Avastin) as frontline maintenance therapy in HRD-positive advanced ovarian cancer. 

Nina Shah, MD and Sandy Wong, MD, discuss the predictive value of minimal residual disease and the need for treatment in a patient with smoldering multiple myeloma.

We recently traveled to Miami, Florida for a State of the Science Summit™ on Gastrointestinal Malignancies, which featured insights from Florida Society of Clinical Oncology faculty.

In an effort to share some of the evolving knowledge about COVID-19 and how it is impacting the healthcare system on a global scale, the Uromigos group discusses statistics, strategies, and new studies as they relate to COVID-19 and patients with genitourinary cancers.

In our exclusive interview, Dr. Hortobagyi shares his journey in the development of anthracyclines and taxanes, biphosphonates, and gene therapies in breast cancer, some of the challenges he has encountered along the way, and what he hopes to tackle in the rest of his monumental career.